The National Institutes of Health financed the case that recruited 25871 healthy American men and women aged 50 and over, including 5 thousand 106 African-Americans. Study participants were divided into four groups and randomly selected to receive supplements or placebo and were followed for an average of 5.3 years.
One group received 2,000 IU (international unit) of vitamin D3 and 1 gram of omega-3 daily. The second group was given a puppet pill instead of vitamin D and omega-3. A third group received omega-3 and a vitamin D placebo. And the last group got two placebo.
In Northridge, Pharmavite LLC donated vitamin D agents and matching placebo and Omacor, a fish oil sold under the brand of Lovaza in the United States by Pronova BioPharma and BASF in Norway.
The results published in the New England Journal of Medicine are presented on Saturday at the American Heart Association conference in Chicago.
In many respects, the results are not surprising. In recent years, there has been a continuous cry of knowledge about the health benefits of vitamin D, as studies link low levels of vitamins to various conditions such as diabetes, hypertension, cancer, heart disease and depression. Many primary care physicians now routinely test patients' vitamin D levels and declare that they are inadequate and have increased sales in recent years.
However, the critics questioned whether vitamin D was an indicator of overall health and whether the threshold of deficiency was too high. Exposed to sunlight and exhausted due to smoking, obesity, poor diet and other factors are synthesized so-called solar vitamins in the body. Some foods, such as fatty fish, eggs and fortified milk, also contain vitamin D.
In 2011, the Medical Institute concluded that most Americans received adequate vitamin D and the deficiencies were exaggerated. The group also noted that potential benefit reports with higher blood levels were inconsistent.